trending Market Intelligence /marketintelligence/en/news-insights/trending/8FWAdhVIjqnxhu-nciG1kA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Regeneron drug shown to reduce bad cholesterol in patients with rare disorder

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Regeneron drug shown to reduce bad cholesterol in patients with rare disorder

Regeneron Pharmaceuticals Inc.'s experimental drug was effective in treating symptoms of patients with a genetic disorder when used with conventional therapy in a late-stage study.

The ongoing phase 3 study, dubbed Elipse, is evaluating efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia, who are already receiving lipid-lowering therapies.

Homozygous familial hypercholesterolemia is a rare condition characterized by high levels of bad cholesterol also known as low-density lipoprotein, or LDL, cholesterol that increases the risk of premature cardiovascular disease and a heart attack. The disorder is estimated to affects about 1,300 people in the U.S., according to the company.

The drug is being tested in 65 patients aged 12 or older in a randomized, parallel-group trial. Of these, 43 patients received 15 milligram/kilogram of evinacumab and 22 were given placebo every four weeks.

Results at week 24 of the study showed that evinacumab, when added to current lipid-lowering therapies, reduced LDL cholesterol in patients by 49% compared to placebo.

The company noted that reduction in LDL cholesterol levels was observed from the first assessment at week two, and was maintained throughout the 24-week treatment period. Evinacumab also reduced apolipoprotein B and non-high-density lipoprotein, or non-HDL, cholesterol, as well as total cholesterol compared to placebo.

About 66% of the patients who received evinacumab and 81% of placebo patients experienced an adverse event during the study.

Regeneron plans to submit data from the study to the regulatory authorities, starting with the U.S. Food and Drug Administration in 2020.

The Tarrytown, N.Y.-based company noted that it will present the detailed results of the study at a future medical meeting.